OBLN - Obalon surges in the pre-market adding to twofold rise this year

Obalon Therapeutics (OBLN) has gained ~28.3% in pre-market trading. With a ~136.0% in the year so far, the medical device company focused on treating obesity has more than tripled in value in the past-12-month period.An article on Own Snap suggests investors ‘put the stock on their watch lists,’ noting ‘Obalon Therapeutics (OBLN) is all set to gap up this morning.’The author Anthony Gonzales observes that Obalon has been a notable gainer among MedTech stocks this year with a ‘remarkable’ 500% gain since its merger announcement with ReShape Lifesciences (RSLP) in January.

For further details see:

Obalon surges in the pre-market adding to twofold rise this year